messenger RNA

Overview

Messenger RNA (mRNA) is a single-stranded ribonucleic acid that carries genetic information from DNA to the ribosome, where it serves as the template for protein synthesis. In biomedicine, mRNA is of major therapeutic interest because it can be engineered to transiently express proteins without altering the genome, making it useful for vaccines, protein replacement, cancer immunotherapy, and genome-editing delivery systems.

As a therapeutic modality, mRNA is typically formulated in delivery vehicles such as lipid nanoparticles to protect it from degradation and promote cellular uptake. Its clinical and experimental value depends on sequence design, translation efficiency, intracellular stability, and tissue-specific delivery. Recent research has expanded mRNA applications beyond vaccination to include CAR T cell engineering, in situ cancer immunotherapy, organ-targeted gene delivery, and delivery of genome-editing components such as Cas9 mRNA and CRISPR-Cas systems.

Focus of Latest Publications

Recent studies have focused on overcoming fundamental barriers to mRNA therapeutic efficacy through advanced lipid nanoparticle (LNP) engineering. Endosomal entrapment after cellular internalization remains a critical bottleneck; researchers have addressed this through programmable mechanical movements using movable lipids, with LED-driven phenylazothiazole lipids integrated into mRNA-LNP cancer vaccine formulations showing enhanced preclinical efficacy. Parallel optimization efforts have explored heparosan polysaccharides as PEG-free surface coatings that reduce immune activation while maintaining efficacy comparable to conventional PEG-modified counterparts. Direct microscopy-based methods now enable precise counting of mRNA molecules within individual LNPs, improving formulation screening and revealing how nucleic acid length influences internal LNP structure, phase behavior, and encapsulation efficiency.

Targeting strategies have significantly enhanced cellular selectivity and transfection efficiency in difficult-to-transfect populations. Antibody-mediated targeting of rapidly cycling T cell receptors CD2 and CD7 improved mRNA-LNP delivery to primary CD4+ T cells both in vitro and in vivo within lymphoid tissues. Peptide-modified LNPs incorporating rationally designed amphiphilic peptide sequences achieved efficient mRNA transfection in historically refractory cell lines such as PC-12 and MCF-7. DNA-tethering methods enabling rapid assembly of bispecific antibody-functionalized LNPs demonstrated improved targeting and transfection efficiency compared to monotargeted variants, with biodistribution modifications supporting organ-specific accumulation when desired.

Organ-specific delivery platforms have enabled tissue-directed mRNA therapeutics with unprecedented precision. Lung-targeted formulations achieved >100-fold improvement in delivery efficiency with 99% targeting specificity and gene editing efficiencies reaching ~70% while demonstrating sustained efficacy across repeated administrations. Systematic screening of 444 lung-targeting lipid candidates revealed a "tripod-like" ionizable lipid structure that achieved 25.5-fold improvement in mRNA delivery and 9.2-fold enhancement in CRISPR-Cas9 efficiency, with >90% lung selectivity. Pancreatic-targeted LNPs exploiting organ-specific capsule filtration principles enabled precise genome editing and delivery of therapeutic cytokine mRNAs for autoimmune disease and cancer applications, with validation in non-human primates. Retinal-targeted formulations identified through systematic design-of-experiments screening achieved 2.6- to 3.0-fold reporter gene expression improvement, localizing mRNA expression to retinal pigment epithelium.

Disease-specific therapeutic applications have demonstrated functional efficacy across inflammatory, genetic, and cardiovascular conditions. In inflammatory bowel disease models, mRNA-loaded LNPs designed to enhance epithelial efferocytic capacity markedly attenuated intestinal inflammation. Familial adenomatous polyposis prevention was achieved through APC-directed mRNA delivery, with treated mice showing significant adenoma burden reduction and restored epithelial barrier function. Cardiac ischemia-reperfusion injury studies revealed temporal, cell-type-specific mRNA-LNP tropism—predominantly affecting myeloid cells early and shifting to fibroblasts and endothelial cells later—providing mechanistic guidance for optimized delivery timing. Acute lung injury models showed IL-10 mRNA delivery via optimized LNPs significantly reduced inflammatory responses. Manufacturing innovations using oscillation-generating micromixing produced uniformly small LNPs (<80 nm with polydispersity index <0.1) and >96% encapsulation efficiency at scalable production rates while maintaining biological functionality. Additionally, microfluidic droplet mechanoporation for T cell engineering achieved mRNA transfection efficiencies approaching 99%, with CRISPR-Cas9 ribonucleoprotein delivery reaching 2.35-fold higher efficiency than electroporation while preserving post-treatment viability and genome integrity.

Key Publications

• NEWJul Mechanical movements generated by movable lipids break endosomal barriers for enhanced mRNA therapeutics. (Science advances, 2026, PMID 42384808): "Lipid nanoparticles (LNPs), composed of ionizable lipids, phospholipids, cholesterol, and PEGylated lipids, have been successfully used in messenger RNA (mRNA) vaccine development."
• NEWJul Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4+ T cells. (Nature communications, 2026, PMID 42386746): "Importantly, targeting CD2 or CD7 enables efficient lipid nanoparticle-mediated delivery of mRNA to T cells in blood and lymphoid tissue in vivo, demonstrating that targeting T cell receptor endocytosis can enhance nanoparticle-mediated drug delivery to T cells."
• Jun Direct Counting of mRNA Copies Inside Individual Lipid Nanoparticles Using In Situ Lysis and Labeling. (Analytical chemistry, 2026, PMID 42210530): "Here we present a single-particle microscopy method that combines direct counting of the mRNA copies per LNP with LNP size measurements."
• May In vivo colonic epithelial cell editing attenuates intestinal inflammation in mice. (Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026, PMID 42154259): "Here, we developed a therapeutic approach to generate epithelial cells with enhanced efferocytic capacity in vivo by delivering mRNA in lipid nanoparticles (LNPs)."
• May Optimization of Lipid Nanoparticles for Safe and Versatile Lung-Targeted RNA Delivery and Disease Therapy. (ACS nano, 2026, PMID 42138142): "In vivo studies demonstrate that Lipid-392 stLNP efficiently delivers mRNA to both endothelial and epithelial cells, achieving gene editing efficiencies of ∼70%."
• May Lipid Nanoparticle Surface Engineering with Heparosan Polysaccharides for Safe and Effective mRNA Delivery In Vitro and In Vivo. (ACS applied materials & interfaces, 2026, PMID 42117531): "We synthesized a library of HEP-coated LNPs and systematically characterized their physicochemical properties, including nanoparticle size, polydispersity, ζ potential, and mRNA encapsulation efficiency."
• Jun Exploring the impact of nucleotide length on lipid nanoparticle structure and properties. (International journal of pharmaceutics, 2026, PMID 42070739): "Lipid nanoparticles (LNPs) are versatile carriers for nucleic acid (NA) therapeutics, including ASOs, siRNA, mRNA, and poly-IC."
• Jun Spatio-temporal targeting of cardiac cells with lipid nanoparticles after myocardial infarction. (Journal of molecular and cellular cardiology plus, 2026, PMID 42064372): "Messenger RNA (mRNA)-based therapies offer a promising alternative for repair and regeneration."
• May Pervasive enhanced transcription in inflammatory breast cancer tumors and PBMCs impacts RNA splicing and intronic RNAs in plasma. (Science advances, 2026, PMID 42066072): "Mirroring gene expression differences in tumors and PBMCs, overrepresented protein-coding gene RNAs in IBC patient plasma were largely intron RNA fragments, while those in non-IBC patient and healthy donor plasma were largely mRNA fragments."
• Apr Peptide-Lipid Nanoparticles Enhance Cell Transfection Efficiency. (Langmuir : the ACS journal of surfaces and colloids, 2026, PMID 41975643): "The resulting LNP-pep formulation achieved efficient mRNA transfection in difficult-to-transfect cell lines, including PC-12 and MCF-7, outperforming unmodified LNPs and commercial reagents."